• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.

作者信息

Gullo G, Zuradelli M, Sclafani F, Santoro A, Crown J

机构信息

Department of Oncology, St Vincent's University Hospital, Dublin, Ireland.

Oncology and Haematology Unit, Humanitas Cancer Center, Rozzano, Italy.

出版信息

Ann Oncol. 2012 Aug;23(8):2204-2205. doi: 10.1093/annonc/mds221. Epub 2012 Jul 5.

DOI:10.1093/annonc/mds221
PMID:22767587
Abstract
摘要

相似文献

1
Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer.化疗联合曲妥珠单抗治疗转移性HER2阳性乳腺癌后的持久完全缓解
Ann Oncol. 2012 Aug;23(8):2204-2205. doi: 10.1093/annonc/mds221. Epub 2012 Jul 5.
2
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.曲妥珠单抗、帕妥珠单抗和化疗新辅助治疗与曲妥珠单抗恩美曲妥珠单抗和帕妥珠单抗联合用于 HER2 阳性乳腺癌患者（KRISTINE）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Oncol. 2018 Jan;19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7. Epub 2017 Nov 23.
3
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report.早期 HER2+ 乳腺癌多西他赛、曲妥珠单抗和卡铂化疗期间发生血栓性微血管病：病例报告。
Med Oncol. 2013;30(2):568. doi: 10.1007/s12032-013-0568-x. Epub 2013 Apr 7.
4
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.多中心 III 期随机临床试验比较多西他赛和曲妥珠单抗与多西他赛、卡铂和曲妥珠单抗作为人表皮生长因子受体 2（HER2）基因扩增转移性乳腺癌（BCIRG 007 研究）一线化疗的疗效：两种高度有效的治疗方案。
J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29.
5
Dual HER2 blockade slows metastatic breast cancer.双重HER2阻断可延缓转移性乳腺癌的进展。
Cancer Discov. 2012 Jan;2(1):OF4. doi: 10.1158/2159-8290.CD-ND121511OL-12. Epub 2011 Dec 15.
6
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
7
Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.帕妥珠单抗、曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌的疗效：一项荟萃分析
Int J Clin Pharmacol Ther. 2017 Sep;55(9):720-727. doi: 10.5414/CP202921.
8
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
9
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.帕妥珠单抗、曲妥珠单抗和多西他赛联合用于人表皮生长因子受体 2 阳性转移性乳腺癌（CLEOPATRA 研究）：一项随机、双盲、安慰剂对照、3 期研究的总生存结果。
Lancet Oncol. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. Epub 2013 Apr 18.
10
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.曲妥珠单抗联合多西他赛或长春瑞滨一线治疗人表皮生长因子受体 2 阳性晚期乳腺癌的回顾性比较。
BMC Cancer. 2010 Feb 1;10:28. doi: 10.1186/1471-2407-10-28.

引用本文的文献

1
Investigating the Correlation Between Long-Term Response in Patients with Metastatic HER2+ Breast Cancer and the Activity of Regulatory T Cells: A Retrospective Study.探讨转移性HER2+乳腺癌患者长期反应与调节性T细胞活性之间的相关性：一项回顾性研究。
Breast Cancer (Dove Med Press). 2024 Sep 27;16:645-655. doi: 10.2147/BCTT.S470570. eCollection 2024.
2
Engineering small-molecule and protein drugs for targeting bone tumors.设计用于靶向骨肿瘤的小分子和蛋白质药物。
Mol Ther. 2024 May 1;32(5):1219-1237. doi: 10.1016/j.ymthe.2024.03.001. Epub 2024 Mar 6.
3
B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
HER2+ 乳腺癌微环境中的 B 细胞和调节性 T 细胞与生存率降低相关：HER2+ 转移性乳腺癌女性的真实世界分析。
Breast Cancer Res. 2023 Oct 4;25(1):117. doi: 10.1186/s13058-023-01717-1.
4
Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer.转移性人表皮生长因子受体2阳性乳腺癌的当前标准与未来展望
Breast Care (Basel). 2023 Feb;18(1):69-75. doi: 10.1159/000528756. Epub 2022 Dec 20.
5
Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018.曲妥珠单抗治疗 HER2 阳性初治转移性乳腺癌的时间：1999-2018 年。
Breast Cancer Res Treat. 2022 Sep;195(2):171-180. doi: 10.1007/s10549-022-06678-1. Epub 2022 Jul 22.
6
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.曲妥珠单抗对基线左心室射血分数降低的 HER2 阳性转移性乳腺癌患者心功能的影响。
Int J Cancer. 2022 Aug 15;151(4):616-622. doi: 10.1002/ijc.34024. Epub 2022 Apr 27.
7
Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone.针对乳腺癌骨转移的抗体疗法的骨特异性增强
ACS Cent Sci. 2022 Mar 23;8(3):312-321. doi: 10.1021/acscentsci.1c01024. Epub 2022 Jan 21.
8
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.一线抗 HER2 靶向治疗转移性乳腺癌长期缓解者无疾病证据与残留疾病。
Br J Cancer. 2022 Apr;126(6):881-888. doi: 10.1038/s41416-021-01676-4. Epub 2021 Dec 20.
9
Harnessing the power of antibodies to fight bone metastasis.利用抗体的力量对抗骨转移。
Sci Adv. 2021 Jun 23;7(26). doi: 10.1126/sciadv.abf2051. Print 2021 Jun.
10
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.获得性拉帕替尼耐药可能使 HER2 阳性乳腺癌细胞对奥巴妥昔单抗和 TRAIL 诱导的细胞凋亡敏感。
BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.